Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung

S. Schreiber; A. U. Dignass; H. Hartmann; W. Kruis; G. Rogler; B. Siegmund; A. Stallmach; C. Witte; B. Bokemeyer

doi:10.1055/s-0034-1399400

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2015; 53(06): 591-602
DOI: 10.1055/s-0034-1399400

Übersicht

Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung

Current position on Vedolizumab for ulcerative colitis and Crohn’s disease

Authors

S. Schreiber

¹Clinic for Internal Medicine I, Kiel, Germany
A. U. Dignass

²Medizinische Klinik I, Markus-Krankenhaus Frankfurter Diakonie-Kliniken, Frankfurt/Main, Germany
H. Hartmann

³Gastroenterologische Gemeinschaftspraxis, Herne, Germany
W. Kruis

⁴Evangelisches Krankenhaus Kalk, Köln, Germany
G. Rogler

⁵Zürich Center for Integrative Human Physiology (ZIHP), Zürich, Switzerland
B. Siegmund

⁶Charité, Berlin, Germany
A. Stallmach

⁷Universitätsklinikum Jena, Germany
C. Witte

⁸DCCV, Berlin, Germany
B. Bokemeyer

⁹Gastroenterologische Gemeinschaftspraxis Minden, Germany

Abstract

Zusammenfassung

Die Therapie mit Vedolizumab, dem ersten in der Medikamentenklasse der antiintegrinblockierenden Moleküle zugelassenen Medikament für Colitis ulcerosa und Morbus Crohn, ist seit Juli 2014 in Deutschland verfügbar. Durch eine spezifische Rezeptorbindung wurde eine relative Darmselektivität ohne die bekannten Nebenwirkungen der systemischen Immunsuppression von Anti-TNF-α-Antikörpern erreicht. Das Nebenwirkungsprofil von Vedolizumab scheint nach den vorliegenden Daten günstiger als das der Anti-TNF-α-Therapie zu sein. Vedolizumab ist für die Induktionstherapie bei Colitis ulcerosa und Morbus Crohn geeignet, wenn auch die Kinetik des Ansprechens gegenüber den Anti-TNF-α-Antikörpern langsamer zu sein scheint. In der Erhaltungstherapie zeigen aber die Vedolizumab-Daten bei einem Ansprechen der Patienten auf die Induktionstherapie eine gute und anhaltende Remissionserhaltung im Langzeitverlauf mit einem geringeren Verlust der Wirksamkeit im Behandlungsverlauf im Vergleich zur Anti-TNF-α-Therapie. Aufgrund der Datenlage scheint die Effizienz von Vedolizumab bei der Colitis ulcerosa eher etwas höher als beim Morbus Crohn zu sein.

Abstract

Vedolizumab, the first drug in the class of anti-integrin molecules, is newly approved for ulcerative colitis and Crohn's disease and can be prescribed in Germany since mid-2014. By a specific receptor binding a relatively gut-selective mode of action was achieved without the known side effects of the systemic immunosuppression of the anti-TNF-alpha antibodies. According to the present data the safety profile of Vedolizumab appears to be more favorable than that of the anti-TNF- alpha therapy. Vedolizumab is suitable for induction therapy in patients with ulcerative colitis and Crohn's disease, however the kinetic of response compared with the anti-TNF-alpha antibodies seems to be slower. For maintenance therapy the Vedolizumab data show a deep and sustained remission in patients initially responding to induction therapy with a lower loss of efficacy in the long-term treatment known from the anti-TNF-alpha therapy. On the basis of currently available data the efficacy of Vedolizumab in ulcerative colitis appears to be slightly better than in Crohn's disease.

Schlüsselwörter

Colitis ulcerosa - Morbus Crohn - chronisch entzündliche Darmerkrankung - Darm

Key words

ulcerative colitis - Crohn's disease - chronic inflammatory bowel disease - GI tract

Volltext

Referenzen

Literatur
1 Timmer A, Breuer-Katschinski B, Goebell H. Time trends in the incidence and disease location of Crohn’s disease 1980 to 1995. A prospective analysis in an urban population in Germany. Inflamm Bowl Dis 1999; 5 (02) 79-84
2 Timmer A, Goebell H. Incidence of ulcerative colitis 1980-1995. A prospective study in an urban population in Germany. Z Gastroenterol 1999; 37: 1079-1084
3 Bokemeyer B. CED-Behandlung in Deutschland. Betrachtungen zur sinnvollen Vernetzung. Der Gastroenterologe 2007; 6 (02) 447-455
4 Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Groub. N Engl J Med 1997; 337: 1029-1035
5 Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
6 Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005; 129: 807-817
7 Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357: 228-238
8 Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapie for fistulizung Crohn‘s disease. N Engl J Med 2004; 350: 876-885
9 Hanauer SB, Feagan BG, Lichtenstein GR. ACCENT I Study Group et al. Maintenance infliximab for Crohn’s disease: the ACCENT 1 randomised trial. Lancet 2002; 359 (9317) 1541-1549
10 Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results for the CLASSIC II trial. GUT 2007; 56: 1232-1239
11 Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030
12 Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
13 Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of randomised controlled trial. Gut 2011; 60: 780-787
14 Sandborn WJ, Feagan BG, Marano C. PURSUIT-Maintenance Study Group et al. Subcutaneous golimumab maintains clinical response in patients with moderate- to severe ulcerative colitis. Gastroenteology 2014; 146: 96-109
15 Targan SR et al. Comparison of Remission at Week 4. The New England journal of medicine 1997; 337: 1029-1035
16 Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: The CLASSIC-I Trial. Gastroenterol 2006; 130: 323-333
17 Baert F, Moortgart L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010; 138: 463-468
18 Bokemeyer B, Helwig U, Teich N et al. TNF-alpha as induction therapy for Crohn's disease: a comparison of adalimumab and infliximab – a prospective observational study in Germany. ECCO 2014. Journal of Crohn's and Colitis 2014; 8 (Suppl. 01) 205
19 Sandborn WJ, Colombel JF, Panes J et al. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn‘s disease: data from precise 2. Am J Gastroenterol 2006; 101: 434-435
20 Schreiber S, Reinisch W, Colombel JF et al. Early Crohn’s disease shows high levels of remission to therapy with Adalimumab: sub-analysis of charm. Gastroenterology 2007; 132: A147
21 Siegel CA, Melmed GY. Predicting Response to Anti-TNF Agents for the Treatment of Crohn’s Disease. Therap Adv Gastroenterol 2009; 2: 245-251
22 Ananthakrishnan AN. Personalizing Therapy for Inflammatory Bowel Disease. Expert Rev Gastroenterol Hepatol 2013; 7: 549-558
23 Spurio FF, Aratari A, Margagnoni G et al. Early Treatment on Crohn’s Disease: Do We Have Enoug Evidence to Reverse the Therapeutic Pyramid?. J Gastroinestin Liver Dis 2012; 21: 67-73
24 Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?. Clinical and Experimental Gastroenterology 2014; 7: 163-172
25 Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33: 987-995
26 Leung Y, Panaccione R. Anti-adhesion molecule strategies for Crohn disease. BioDrugs 2008; 22: 259-264
27 Gisbert JP, Panés J. Loss of response and requirement of Infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104: 760-767
28 Van Assche G, Vermeire S, Ballet V et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. GUT 2012; 61: 229-234
29 Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838
30 Milch C, Wyant T, Xu J et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013; 264: 123-126
31 Targan SR, Feagan BG, Fedorak RN et al. International Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683
32 Sandborn WJ. The future of inflammatory bowel disease therapy: where do we go from here?. Dig Dis 2012; 30 (Suppl. 03) 140-144
33 Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353: 1912-1925
34 FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associatet with Tysabri (Natalizumab). webpage on the Internet. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm Accessed October 30, 2013
35 Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
36 Feagan BG, Rutgeerts P, Sands BE. GEMINI 1 Study Group et al. Vedolizumab as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med 2013; 369: 699-710
37 Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687
38 Yednock TA, Cannon C, Fritz LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66
39 Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66
40 Lawrence IC. What is left when anti-tumor necrosis factor therapy in inflammatory bowel diseases fails?. World J Gastroenterol 2014; 20: 1248-1258
41 Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314
42 Ahiro S, Ohtani H, Suzuki M et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s disease. Pathol Int 2002; 52: 367-374
43 Briskin M, Winsor-Hines D, Shyjan A et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110
44 Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078
45 Allorca M, Fiorino G, Vermeire S et al. Blockade of lymphocyte trafficking in inflammatory bowel disease therapy: importance of specificity of endothelial target. Expert Rev Clon Immunol 2014; 10: 885-895
46 Wyant T, Leach T, Sankoh S et al. Vedolizumab affects antibody response to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2014; Published Online First: 24 April 2014.
47 Vermeire S, O’Byrne S, Keir M et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384: 309-318
48 Armuzzi A, Felice C. Etrolizumab in moderate-to-severe ulcerative colitis. Lancet 2014; 384: 285-286
49 Werr J, Johansson J, Eriksson E et al. Integrin α2β1 (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue. Blood 2000; 95: 1804-1809
50 Pan WJ, Hsu H, Rees Wa et al. Pharmacology of AMG 181, a human anti- α4β7 antibody that specifically alters trafficking of gut-homing T cells. British Journal of Pharmacology 2013; 169: 51-68
51 Parikh A, Leach T, Wyant T et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflammat Bowel Dis 2012; 18: 1470-1479
52 Ordas I, Mould DR, Feagan BG et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-646
53 Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-2507
54 Gledhill T, Bodger K. New and emerging treatment for ulcerative colitis: a focus on Vedolizumab. Biologics 2013; 7: 123-130
55 Shukla R, Vender RB. Pharmacology of TNF inhibitors. In: Weinberg JM, Buchholz R. TNF-alpha Inhibitors. Milestones in Drug Therapy. Springer Verlag.: 2006. ISBN: 978-3-7643-7248-4
56 Assesment Report for Simponi. EPAR – European Medicines Agency. [webpage on the Internet]. Available from: 2009 http://www.ema.europa.eu/docs/enGB/document _library/EPAR_-_Public_assessment_report/human/000992/WC500052372.pdf
57 Brandse JF, Wildenberg M, de Bruyn JR et al. Fecal Loss of Infliximab as a Cause of Lack of Response in Severe Inflammatory Bowel Disease. Gastroenterology 2013; 144 (Suppl. 01) 36
58 Armuzzi A, Biancone L, Daperno M et al. Italien Group for the Study of Inflammatory Bowel Disease. Adalimumab in active ulcerative colitis: a “real-life” observational study. Dig Liver dis 2013; 45: 738-743
59 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
60 Feagan B, Rutgeerts P, Sands B et al. Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I a Randomized Placebo-Controlled, Double-Blind Multicenter Phase 3 Trial. Abstract 1522, ACG Oct 2012
61 Hanauer S, Colombel JF, Feagan B et al. Vedolizumab Maintenance Therapy for Crohn’s Disease: Results of GEMINI II a Randomized Placebo-Controlled, Double-Blind Multicenter Phase 3 Trial. The American Journal of Gastroenterology 2012; 107: S608
62 Sands BE, Feagan BG, Rutgeerts P et al. Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology 2014; 147: 618-627
63 Colombel JF. Adalimumab for fistulas in patients with Crohn's disease. Gut 2009; 58: 940-940
64 Ford AC. Efficacy of Biological Therapies in IBD: Systematic Review and Meta-Analysis. Am J Gastroenterol 2011; 106: 644-659
65 Lichtenstein GR, Feagan BG, Russel DC et al. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry. Am J Gastroenterol 2012; 107: 1409-1422
66 Burmester GR, Pannaccione R, Gordon KB et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013; 72: 517-524
67 Long MD, Martin CF, Pipkin CA et al. Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-399
68 Everett SM, Hamlin PJ. Evidence-based Use of Anti-TNF alpha Therapie in Crohn’s Disease. Frontline Gastroenterol 2011; 2: 144-150
69 Frøslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133,412-422
70 Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
71 Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel disease: a systematic review. Gut 2012; 61: 1619-1635
72 Chevaux JB, Vavricka SR, Rogler G et al. Mucosal healing with anti-TNF antibodies. Digestion 2012; 86 (Suppl. 01) 16-22
73 Barreiro-de Acosta M, Vallejo N, de la Iglesia D et al. Mucosal healing in ulcerative colitis: Do Mayo 0 and 1 scores really have the same prognostic value? A prospektive observational cohort study. J Crohns Colitis 2014; 8: S38-S39
74 Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61 (12) 1693-1700
75 Schreiber S, Fedorak RN, Nielsen OH et al. Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn’s Disease. Gastroenterology 2000; 119: 1461-1472
76 Geramia A, Biancheri P, Allan P et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13: 3-10
77 Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to Severe Ulcerative Colitis. Gastroenterology 2014; 146: 85-95
78 Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance Therapy with Certolizumab Pegol for Crohn’s Disease. N Engl J Med 2007; 357: 239-250
79 Sandborn WJ, Van Assche G, Reinisch W et al. Adalimumab Induces an Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2012; 142: 257-265
80 Pariente B, Cosnes J, Danese S et al. Development of Crohn’s disease digestive damage scor, the Lémann score. Inflamm Bowel Dis 2011; 17: 1415-1422
81 Danese S, Fiorino G, Peyrin-Birolet L et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review an network meta-analysis. Ann Intern Med 2014; 160: 704-711
82 Sands BE. Maintenance infliximab in ACCENT II study. Aliment Pharmacol Ther 2006; 23: 1127-1136
83 Talley NJ. An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease. Am J Gastroenterol 2011; 106: 2-25
84 Sandborn WJ, Feagan BG, Rutgeerts P. GEMINI 2 Study Group. et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
85 Feagan BG, Rutgeerts P, Sands BE. GEMINI 1 Study Group et al. Vedolizumab as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med 2013; 369: 699-710
86 Sands BE, Kozarek R, Spainhour J et al. Safety and tolerability of concurrent Natalizumab treatment for patients with Crohn´s disease not in remission while receiving infliximab. Inflamm Bowel Dis 13: 2-11
87 Sun H, Liu J, Zheng Y et al. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cell 2014; 30: 61-70
88 Keshav S, Vaňásek T, Niv Y. . Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLos One 2013; 8: e60094
89 Rosenstiel P, Agnholt J, Kelsen J et al. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. Gut 2005; 54: 314-315
90 Schreiber S, Feagan B, D'Haens G et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 325-334